{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T04:10:52Z","timestamp":1794370252530,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2021\/23-QA253"],"award-info":[{"award-number":["2021\/23-QA253"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2021\/23-QA253"],"award-info":[{"award-number":["2021\/23-QA253"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["2021\/23-QA253"],"award-info":[{"award-number":["2021\/23-QA253"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Emerging evidence suggests gut microbiota differences in Parkinson\u2019s Disease (PD) may impact disease progression and treatment. Faecal Microbiota Transplantation (FMT) offers a potential therapeutic approach. We conducted an open-label pilot study to assess the safety, tolerability, and symptom impact of FMT in 12 patients with mild to moderate PD, administered via enema for 6 months. FMT was safe and well tolerated, causing only mild, transient gastrointestinal symptoms. While no significant motor symptom changes were observed, there was a trend toward reduced daily OFF time at 2 months. Whilst no sustained improvement in non-motor symptoms was found after 6 months, transient improvements in quality of life and non-motor scores were noted at 2 months; these gains regressed by study end. Overall, extended FMT therapy in PD appears safe and tolerable, with reduction in daily motor OFF time and self-reported non-motor symptoms that was not sustained throughout the 6-months of treatment<\/jats:p>","DOI":"10.1038\/s41531-025-01061-5","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:54:40Z","timestamp":1752137680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Faecal microbiota transplant in Parkinson\u2019s disease: pilot study to establish safety &amp; tolerability"],"prefix":"10.1038","volume":"11","author":[{"given":"Michele","family":"De Sciscio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haylock-Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice S.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pitchers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Iansek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel P.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Kimber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"key":"1061_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic, J. & Tan, E. K. Parkinson\u2019s disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry 91, 795\u2013808 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1061_CR2","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fnins.2019.00369","volume":"13","author":"E Fitzgerald","year":"2019","unstructured":"Fitzgerald, E., Murphy, S. & Martinson, H. A. Alpha-synuclein pathology and the role of the microbiota in Parkinson\u2019s disease. Front Neurosci. 13, 369 (2019).","journal-title":"Front Neurosci."},{"key":"1061_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.570658","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu, J., Xu, F., Nie, Z. & Shao, L. Gut microbiota approach-a new strategy to treat Parkinson\u2019s disease. Front Cell Infect. Microbiol. 10, 570658 (2020).","journal-title":"Front Cell Infect. Microbiol."},{"key":"1061_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. & Borghammer, P. Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940\u2013949 (2016).","journal-title":"Ann. Neurol."},{"key":"1061_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00702-002-0808-2","volume":"110","author":"H Braak","year":"2003","unstructured":"Braak, H., R\u00fcb, U., Gai, W. & Del Tredici, K. Idiopathic Parkinson\u2019s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517\u2013536 (2003).","journal-title":"J. Neural Transm."},{"key":"1061_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans, F. et al. Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov. Disord. 30, 350\u2013358 (2015).","journal-title":"Mov. Disord."},{"key":"1061_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.02.022","author":"A Schwiertz","year":"2018","unstructured":"Schwiertz, A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat. Disord. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.022 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1061_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger, M. M., Spiegel, J. & Dillmann, K. Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66\u201372 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1061_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-00775-7","volume":"18","author":"F Baldini","year":"2020","unstructured":"Baldini, F. et al. Parkinson\u2019s disease-associated alterations of the gut microbiome predict disease- relevant changes in metabolic functions. BMC Biol. 18, 62 (2020).","journal-title":"BMC Biol."},{"key":"1061_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun, M. F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: gut microbiota, glial reaction and TLR4\/TNF-alpha signaling pathway. Brain Behav. Immun. 70, 48\u201360 (2018).","journal-title":"Brain Behav. Immun."},{"key":"1061_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL DuPont","year":"2023","unstructured":"DuPont, H. L. et al. Fecal microbiota transplantation in Parkinson\u2019s disease-A randomized repeat-dose, placebo-controlled clinical pilot study. Front Neurol. 14, 1104759 (2023).","journal-title":"Front Neurol."},{"key":"1061_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102563","volume":"71","author":"A Bruggeman","year":"2024","unstructured":"Bruggeman, A. et al. Safety and efficacy of faecal microbiota transplantation in patients with mild to moderate Parkinson\u2019s disease (GUT-PARFECT): a double-blind, placebo-controlled, randomised, phase 2 trial. EClinicalMedicine 71, 102563 (2024).","journal-title":"EClinicalMedicine"},{"key":"1061_CR13","doi-asserted-by":"publisher","first-page":"e22035","DOI":"10.1097\/MD.0000000000022035","volume":"99","author":"LJ Xue","year":"2020","unstructured":"Xue, L. J. et al. Fecal microbiota transplantation therapy for Parkinson\u2019s disease: a preliminary study. Med. (Baltim.). 99, e22035 (2020).","journal-title":"Med. (Baltim.)."},{"key":"1061_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/jamaneurol.2024.2305","volume":"81","author":"F Scheperjans","year":"2024","unstructured":"Scheperjans, F. et al. Fecal Microbiota transplantation for treatment of parkinson disease: a randomized clinical trial. JAMA Neurol. 81, 925\u2013938 (2024).","journal-title":"JAMA Neurol."},{"key":"1061_CR15","first-page":"33","volume":"53","author":"C Marcella","year":"2021","unstructured":"Marcella, C. et al. Systematic review: the global incidence of faecal microbiota transplantation-related adverse events from 2000 to 2020. APT 53, 33\u201342 (2021).","journal-title":"APT"},{"key":"1061_CR16","unstructured":"Muhammad, A. & Abideen, Z. Fecal microbiota transplantation in patients with Parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials (2025)."},{"key":"1061_CR17","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","volume":"31","author":"S Porcari","year":"2023","unstructured":"Porcari, S. et al. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic. Cell Host Microbe 31, 712\u2013733 (2023).","journal-title":"Cell Host Microbe"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jgh3.12874","volume":"7","author":"EC Tucker","year":"2023","unstructured":"Tucker, E. C. et al. Stool donor screening within a Therapeutic Goods Administration compliant donor screening program for fecal microbiota transplantation. JGH Open. 7, 172\u2013177 (2023).","journal-title":"JGH Open."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01061-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01061-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:28:23Z","timestamp":1757215703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01061-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01061-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6190300\/v1","asserted-by":"object"}]},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RV Bryant and SP Costello are shareholders in BiomeBank. However, the research was performed in keeping with good clinical practice with appropriate governance and oversight (including a safety monitoring board) to mitigate this conflict.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by Central Adelaide Local Health Network Human Research Ethics Committee (# 2021\/HRE00012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical compliance statement"}}],"article-number":"203"}}